Rational PPI therapy: risks and benefits of prolonged use of proton pump inhibitors in the updated recommendations of experts of the American Gastroenterological Association

Yu.M. Stepanov

Abstract


The article presents updated practical recommendations of the American Gastroenterological Association on the long-term use of proton pump inhibitors (PPI). Ten recommendations, formulated by a group of reputable American gastroenterologists, led by D.E. Freedberg, are based on an extensive review and analysis of the quality of evidence of the absolute and relative risks and benefits of PPI therapy, given in the most significant current researches, and are designed to help clinicians choose the safest and most effective methods of treatment for patients with PPI.

Keywords


proton pump inhibitors; eradication therapy; Helicobacter pylori; gastrointestinal tract

References


Tkachenko EI, Uspenskii YP, Pakhomova IG, Baryshnikova NV. Gastroesophageal reflux disease: a new solution to an old problem. Novosti Meditsiny i Farmatsii. 2010;5(311). Available from: http://www.mif-ua.com/archive/article/11809

Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43(12):1262-75. doi: 10.1111/apt.13642.

Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. doi:10.1186/s12916-016-0718-z.

Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-715. doi: 10.1053/j.gastro.2017.01.031.

http://www.gradeworkinggroup.org

Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545-53. doi: 10.1111/j.1365-2036.2007.03407.x.

Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med 2016;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193.

Ivanov DD. Chronic kidney disease. Novosti Meditsiny i Farmatsii. 2010;7(320). Available from: http://www.mif-ua.com/archive/article/12230

Xie Y, Bowe B, Li T, et al. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol. 2016 Oct;27(10):3153-63. doi: 10.1681/ASN.2015121377.

Akter S, Hassan MR, Shahriar M, Akter N, Md. G. Abbas G, et al. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res Ther. 2015; 7: 79. doi: 10.1186/s13195–015–0164–8.

Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419-28.

Gomm W, von Holt K, Thome F, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol 2016; 73:410-6. doi: 10.1001/jamaneurol.2015.4791.

Tuukkanen J, Väänänen HK. Omeprazole, a specific inhibitor of H+К+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123-5. PMID: 3006888.

Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107:1361-9. doi: 10.1038/ajg.2012.200.

Maggio M, Lauretani F, Ceda GP, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57:437-42. doi: 10.1016/j.bone.2013.09.014.

Targownik L, Luo Y, Goertzen A, et al. Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. Am J Gastroenterol. 2017;112:95-101. doi:10.1038/ajg.2016.481.

Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-17. doi: 10.1056/NEJMoa1007964.

Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128:845-53. doi: 10.1161/CIRCULATIONAHA.113.003602.

Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One. 2015 Jun 10;10(6):e0124653. doi: 10.1371/journal.pone.0124653. eCollection 2015.

Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12:99-104. PMID: 9692707.

Lewis SJ, Franco S, Young G, et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10:557-61. PMID: 8853759.

Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013 May;11(5):483-90. doi: 10.1016/j.cgh.2012.12.011.

Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1269-81. doi: 10.1111/j.1365-2036.2011.04874.x.

Brophy S, Jones KH, Rahman MA, et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol. 2013 Jul;108(7):1094-100. doi: 10.1038/ajg.2013.30.

Xu HB, Wang HD, Li CH, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015 Jul 6;14(3):7490-501. doi: 10.4238/2015.July.3.25.

Freedberg DE, Toussaint NC, Chen SP, et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology. 2015 Oct;149(4):883-5.e9. doi: 10.1053/j.gastro.2015.06.043.

Furuya-Kanamori L, Stone JC, Clark J, et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015 Feb;36(2):132-41. doi: 10.1017/ice.2014.39.

Dubberke ER, Reske KA, Yan Y, et al. Clostridium difficile–associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007 Dec 15;45(12):1543-9. doi: 10.1086/523582.

Freedberg DE, Lamouse-Smith ES, Lightdale JR, et al. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis. 2015 Sep 15;61(6):912-7. doi: 10.1093/cid/civ432.

Rosen R, Hu L, Amirault J, et al. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr. 2015 Apr;166(4):917-23. doi: 10.1016/j.jpeds.2014.12.067.

Lambert AA, Lam JO, Paik JJ, et al. Risk of community- acquired pneumonia with outpatient proton-pump in- hibitor therapy: a systematic review and meta-analysis. PLoS One. 2015 Jun 4;10(6):e0128004. doi: 10.1371/journal.pone.0128004. eCollection 2015.

Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid- suppressive drugs. JAMA. 2004 Oct 27;292(16):1955-60. DOI: 10.1001/jama.292.16.1955.

Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391-8. PMID: 18794558.

Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011 May;97(10):797-802. doi: 10.1136/hrt.2010.217547.

Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015 Sep;42(5):607-13. doi: 10.1111/apt.13304.

Krag M, Perner A, Wetterslev J, et al. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014 Jan;40(1):11-22. doi: 10.1007/s00134-013-3125-3.

O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778-81. doi: 10.1016/j.amjmed.2005.02.007.

Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med. 1967;66:917-23. PMID: 6025232.

Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phos- phorus, magnesium or zinc from food in humans J Am Coll Nutr. 1995 Aug;14(4):364-8.

Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998 Jan;12(1):83-98.

Hutchinson C, Geissler CA, Powell JJ, et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56:1291-5. doi: 10.1136/gut.2006.108613.

Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355:1834-6. DOI: 10.1056/NEJMc066308.

Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015 Aug;37(7):1237-41. doi: 10.3109/0886022X.2015.1057800.

Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013 Dec 11;310(22):2435-42. doi: 10.1001/jama.2013.280490.

den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long- term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008 Mar 15;27(6):491-7. doi: 10.1111/j.1365-2036.2008.03601.x.

Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006;55:1538-44. doi: 10.1136/gut.2005.086579.

Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014 Dec 2;(12):CD010623. doi: 10.1002/14651858.CD010623.pub2.

Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015 Jun;41(11):1162-74. doi: 10.1111/apt.13194.

Thorburn CM, Friedman GD, Dickinson CJ, et al. Gastrin and colorectal cancer: a prospective study. Gastroenterology. 1998;115: 275-80.

Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755-60. doi: 10.1053/j.gastro.2007.06.014.

Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106-10. doi: 10.1056/NEJM199510263331703.

Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology. 1994;107:1312-8. PMID: 7926495.

Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient- directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther. 2004;19: 917-22. DOI: 10.1111/j.1365-2036.2004.01928.x.

Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis–a placebo- controlled randomized trial. Aliment Pharmacol Ther. 1999;13:907-14. PMID: 10383525.

Pace F, Tonini M, Pallotta S, et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ’on-demand’. Aliment Pharmacol Ther. 2007;26:195-204. doi: 10.1111/j.1365-2036.2007.03381.x.

Sarr MG, Hamilton SR, Marrone GC, et al. Barrett’s esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux. Am J Surg. 1985;149:187-93. PMID: 3966636.

Chey WD, Inadomi JM, Booher AM, et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100:1237-42. doi: 10.1111/j.1572-0241.2005.41364.x

Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727-34. doi: 10.1056/NEJM199803123381105.

Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101:701-10. doi: 10.1111/j.1572-0241.2006.00499.x.

Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007 May 12;369(9573):1621-6. doi: 1016/S0140-6736(07)60749-1.

Fass R, Inadomi J, Han C, et al. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53. doi: 10.1016/j.cgh.2011.11.021.

Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121:1095-100. PMID: 11677201.

Sjöstedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther. 2005;22:183-91. doi: 10.1111/j.1365-2036.2005.02553.x.

Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006 Oct;55(10):1398-402. DOI: 10.1136/gut.2005.087668.

Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013 May 31;(5):CD006095. doi: 10.1002/14651858.CD006095.pub3.

Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006 Feb 16;354(7):669-83. doi: 10.1056/NEJMoa055218.

Bailey RL, Dodd KW, Goldman JA, et al. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr. 2010 Apr;140(4):817-22. doi: 10.3945/jn.109.118539.




DOI: https://doi.org/10.22141/2308-2097.51.2.2017.101704

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru